Spark Therapeutics gene therapy reduces bleeding in hemophilia A trial

Spark Therapeutics, the biotechnology company focused on gene therapy, says its experimental treatment for hemophilia A reduced bleeds and the need for therapeutic infusions by 97 percent in a trial of 12 patients. Wall Street was looking for a level of at least 30 percent to consider the trial a success, Evercore ISI analyst Steve Breazzano says.